Stock listing

NASDAQ:CADL Candel Therapeutics, Inc. Stock

Home listing (NASDAQ) of Candel Therapeutics, Inc.

Follow Candel Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CADL

$5.04 USD -0.28 (-5.3%)

Close on Nov 20, 2026

Past year +14.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.90 – $5.31 USDNov 20, 2026
Volume
1.72M sharesNov 20, 2026
Market cap
$395.4M USDAt the close on Nov 20, 2026 · price × 78.45M shares outstanding
52-week range
$4.35 – $14.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$12.16M USDMedian day 989,443 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Candel Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CADL · Home$5.04 USD-0.28 (-5.3%)1,723,500$5.00$5.31$4.90$5.32Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CADL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$5.04-0.28-5.3%$5.00$5.31$4.901,723,500
$5.32-0.08-1.5%$5.35$5.637$5.261,389,374
$5.40-0.41-7.1%$5.78$6.04$5.331,803,756
$5.81-0.39-6.3%$5.94$6.23$5.7253,269,772
$6.20-2.19-26.1%$5.325$6.63$5.206,622,128
$8.39-0.83-9.0%$9.11$9.21$8.3351,935,346
$9.22-0.13-1.4%$9.53$9.54$9.181,096,934
$9.35-0.14-1.5%$9.40$9.65$9.089623,545
$9.49+0.74+8.5%$8.99$9.84$8.651,371,305
$8.75+0.71+8.8%$8.24$8.75$8.06955,020
$8.04-1.01-11.2%$8.98$9.009$7.921,228,485
$9.05+0.23+2.6%$8.93$9.33$8.71993,819
$8.82+0.70+8.6%$8.19$8.86$8.193,304,421
$8.12-0.21-2.5%$8.35$8.61$8.011862,017
$8.33-0.32-3.7%$8.56$8.61$8.16779,925
$8.65-0.02-0.2%$8.72$8.93$8.553740,959
$8.67+0.42+5.1%$8.13$8.69$8.13663,859
$8.25+0.46+5.9%$7.78$8.37$7.741928,461
$7.79-0.24-3.0%$8.44$8.44$7.70849,302
$8.03-0.35-4.2%$8.33$8.33$7.9051,184,816
$8.38+0.01+0.1%$8.45$8.79$8.255762,579
$8.37-0.27-3.1%$8.65$8.82$8.351,102,647
$8.64+0.43+5.2%$8.17$8.84$8.1251,126,151
$8.21+0.02+0.2%$8.37$8.499$7.961,278,696
$8.19-0.72-8.1%$8.92$8.92$8.1251,513,092
$8.91-0.16-1.8%$9.01$9.10$8.79989,338
$9.07-0.20-2.2%$9.06$9.43$9.03989,443
$9.27-0.51-5.2%$9.78$9.845$9.221,133,162
$9.78-0.16-1.6%$10.00$10.18$9.71744,631
$9.94+0.28+2.9%$9.69$9.95$9.59718,368
$9.66-0.16-1.6%$9.70$9.755$9.45888,496
$9.82-0.05-0.5%$9.75$9.945$9.60714,954
$9.87-0.36-3.5%$10.32$10.40$9.85977,769
$10.23+0.05+0.5%$10.27$10.45$9.94980,886
$10.18+0.02+0.2%$10.29$10.37$10.03878,803
$10.16-0.28-2.7%$10.72$10.72$10.161,037,610
$10.44-0.44-4.0%$11.02$11.25$10.371,268,853
$10.88-0.31-2.8%$11.25$11.25$10.57963,288
$11.19+0.17+1.5%$10.98$11.52$10.76771,016
$11.02-0.53-4.6%$11.50$11.55$11.01799,764
$11.55+0.26+2.3%$11.22$11.59$10.85883,107
$11.29-0.56-4.7%$11.93$12.01$11.271,287,820
$11.85+0.64+5.7%$11.28$11.96$11.15882,043
$11.21+0.36+3.3%$11.85$11.90$11.131,086,919
$10.85-0.49-4.3%$11.28$11.38$10.783,014,534
$11.34+0.32+2.9%$10.95$11.50$10.86798,618
$11.02-0.10-0.9%$11.16$11.43$10.831,168,698
$11.12+0.445+4.2%$10.63$11.14$10.411,065,387
$10.68+0.13+1.2%$10.41$10.97$10.32940,804
$10.55-0.785-6.9%$11.32$11.41$9.8553,596,201
$11.33-0.84-6.9%$12.05$12.05$11.201,952,924
$12.17-0.43-3.4%$12.52$12.78$12.13661,253
$12.60-0.18-1.4%$12.57$12.85$12.021,002,103
$12.78-0.19-1.5%$12.91$13.05$12.76535,822
$12.97-0.23-1.7%$13.21$13.28$12.73628,312
$13.20+0.35+2.7%$12.81$13.41$12.67807,852
$12.85-0.22-1.7%$12.93$13.04$12.60935,641
$13.070.000.0%$13.02$13.22$12.63895,013
$13.07-0.68-4.9%$13.64$13.80$12.881,236,463
$13.75+0.47+3.5%$13.26$14.00$13.201,185,355
$13.28-0.32-2.4%$13.60$13.85$13.19977,998
$13.60+0.74+5.8%$13.09$13.95$12.971,342,938
$12.86-0.27-2.1%$12.99$12.99$12.40959,088
$13.13+0.78+6.3%$12.52$13.26$12.381,339,298
$12.35-1.15-8.5%$13.23$13.38$12.331,541,934
Ticker
NASDAQ:CADL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Candel Therapeutics, Inc. news

Candel Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 133 in all · newest Nov 12, 2026 · oldest 2021
Decks
14 decks · latest September 2026

Where Candel Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CADL · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CADLBOATSUnited StatesUSD

Valuation

Price/book 3.0× against a median of 4.2×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$193.8M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
2.03

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Candel Therapeutics, Inc. · NASDAQ:CADLUS$395.4MUS$193.8Mn/an/an/a3.0×n/a0.0×2.03
Jacobio Pharmaceuticals Group Co., Ltd. · HKEX:1167US$401.1MUS$173.5Mn/a22.2×n/a2.0×−272.7%0.1×n/a
Ever Supreme Bio Technology Co., Ltd. · TPEX:6712US$394.8MUS$362.8M27.5×11.1×23.9×4.6×43.8%0.0×n/a
Mezzion Pharma Co., Ltd. · KRX:140410US$391.0MUS$360.8Mn/a57.3×n/a13.4×−325.0%0.0×n/a
Avalo Therapeutics, Inc. · NASDAQ:AVTXUS$390.9M−US$1.93Mn/an/an/a0.9×n/a0.0×1.25
Qurient Co., Ltd. · KRX:115180US$388.5MUS$372.4Mn/a70.5×n/a30.2×−543.0%0.8×n/a
Beijing Luzhu Biotechnology Co., Ltd. Class H · HKEX:2480US$388.2MUS$369.1Mn/an/an/a4.3×n/a0.4×n/a
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378US$387.5MUS$316.0Mn/an/an/a4.1×n/a0.1×n/a
Opus Genetics, Inc. · NASDAQ:IRDUS$385.7MUS$332.3Mn/a42.0×n/a10.0×n/a0.9×1.01
Eupraxia Pharmaceuticals, Inc. · TSX:EPRXUS$384.3MUS$252.7Mn/an/an/a2.9×n/a0.0×1.53
Hinova Pharmaceuticals, Inc. Class A · SSE:688302US$381.1MUS$285.9Mn/a23.0×n/a2.6×−167.3%0.1×n/a
Median of the othersUS$388.4MUS$324.2M27.5×32.5×23.9×4.2×−272.7%0.1×1.25

Forecasts

10 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
19.11 USD · Analysts' mean
EPS, year to Dec 2026
-1.08 · 3 analysts

Team and board

Officers

OfficerRole
Paul Peter TakPresident & Chief Executive Officer
Charles SchochChief Financial Officer
Edward J. BenzPresident
Gary NabelPresident
Maria OstrovskyGeneral Counsel
Theodore JenkinsVice President
Francesca BaroneChief Scientific Officer
Henry BremDirector, Department of Neurosurgery
James P. AllisonChief of the Department of Immunology
Mark SimsChief Commercial Officer
Philip KantoffCo-Founder, Convergent Therapeutics
Roy HerbstDirector, Dartmouth Cancer Center
Seshu TyagarajanChief Technical and Development Officer
Susan StewartChief Regulatory Officer
W. Garrett NicholsChief Medical Officer

Board

DirectorRole
Joseph PapaChairman
Paul B. ManningChair of the Board
Elizabeth JaffeeDeputy Director
Martine ZimmermannDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−26.1%
Q2 2026Aug 13, 2026 · Before open+10.5%
Q1 2026May 14, 2026 · Before open−0.3%
Q4 2025Mar 26, 2026−3.6%
Q3 2025Nov 13, 2025 · Before open−6.3%
Q2 2025Aug 14, 2025 · Before open−5.6%
Q1 2025May 13, 2025 · Before open+7.7%
Q4 2024Mar 13, 2025+8.2%
Q3 2024Nov 14, 2024−11.4%
Q2 2024Aug 13, 2024−5.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open+4.9%
Q4 2023Mar 28, 2024 · Before open+2.6%
Q3 2023Nov 9, 2023 · Before open−13.0%
Q2 2023Aug 10, 2023 · Before open−3.6%
Q1 2023May 11, 2023 · Before open−3.4%
Q4 2022Mar 30, 2023 · Before open−2.0%
Q3 2022Nov 10, 2022 · Before open+10.7%
Q2 2022Aug 5, 2022 · Before open+1.4%
Q1 2022May 12, 2022 · Before open+3.5%
Q4 2021Mar 29, 2022 · Before open−2.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck73 slidesSeptember 2026
Corporate Update (May 2026)Corporate update23 slidesMay 15, 2026
AUA 2026Conference17 slidesMay 2026
Investor Day (December 2025)Investor day80 slidesDec 5, 2025
ASTRO 2025Conference19 slidesSeptember 2025
ASCO 2025Conference18 slidesMay 27, 2025
Investor Presentation (March 2025)Investor deck47 slidesMar 27, 2025
Technical Presentation (December 2024)Technical41 slidesDec 11, 2024
Rotterdam IOVC 2024Conference32 slidesOct 28, 2024
Technical Presentation (January 2024)Technical46 slidesJan 17, 2024
All 14 decks
DeckKindSlidesDate
Technical Presentation (May 2023)Technical23 slidesMay 19, 2023
ASGCT 2023Conference23 slidesMay 2023
Investor Day (December 2022)Investor day107 slidesDec 6, 2022
Breakfast Event during ASCO 2022 Annual MeetingConference46 slidesJun 6, 2022

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: US$100M · US$5.45 a share · Citigroup +5
Dealers: LifeSci Capital (lead), Citigroup (co-lead), Cantor (co-lead), Stifel (co-lead), H.C. Wainwright & Co., Brookline Capital Markets
Use of proceeds: Launch readiness and commercial activities for aglatimagene in prostate cancer, phase 3 NSCLC trial costs, and general corporate purposes
Feb 20, 2026
Registered direct offering of common stock
Announced: about US$15M · US$4.67 a share
Insiders: Investors include executive officers and members of the Company's Board of Directors.
Use of proceeds: Launch readiness, medical affairs and pre-commercialization for CAN-2409 in prostate cancer ahead of a BLA submission, and general corporate purposes
Jun 24, 2025
Public offering of common stock and pre-funded warrants
Closed: US$92M raised · US$6 a share · Citigroup +3
Dealers: Citigroup (co-lead), BofA Securities (co-lead), Canaccord Genuity (co-lead), H.C. Wainwright & Co.
Use of proceeds: Continue development of product candidates, including preparing a BLA submission for CAN-2409 in prostate cancer, and general corporate purposes
Dec 16, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$8.00 a share on Jul 26, 2021.

Price
US$8.00 a share
Shares offered
9,000,000 shares of common stock
Offering size
US$72 million
Underwriters' option
Up to 1,350,000 more shares
Underwriters
Jefferies, Credit Suisse, BMO Capital Markets, UBS Investment Bank · In the order on the cover
Shares delivered
On or about Jul 29, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 16, 2021
Filed publiclyJun 25, 2021
Amended 3 timesNewest Jul 26, 2021
Shares registered with an exchangeJul 19, 2021
Declared effective by the SECJul 26, 2021
Final prospectus, with the priceJul 28, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 28, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0031.0K125.0K125.0K125.0K125.0K
Cost of revenue845.0K990.0K24.0M987.0K232.0K6.61M
Gross profit-845.0K-990.0K-24.0M125.0K125.0K125.0K125.0K
Research and development30.5M19.3M24.5M20.8M15.2M8.75M6.61M
Selling, general and administrative17.8M14.1M13.9M14.1M10.7M5.18M2.56M
Operating income-48.3M-33.4M-38.4M-34.7M-25.7M-13.8M-9.04M
Depreciation and amortization845.0K990.0K960.0K778.0K232.0K91.0K43.0K
EBITDA-47.4M-32.4M-37.4M-33.9M-25.5M-13.7M-8.99M
Interest expense2.12M2.09M-2.60M1.71M53.0K111.0K1.07M
Income before tax-38.2M-55.2M-37.9M-18.8M-36.1M-17.7M-8.24M
Income tax000004.49M-226.0K
Net income-38.2M-55.2M-37.9M-18.8M-36.1M-17.7M-8.24M
Earnings per share, basic-0.72-1.74-1.31-0.65-1.91-1.52-0.44
Earnings per share, diluted-0.72-1.74-1.31-0.65-1.91-1.52

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents119.7M102.7M35.4M70.1M82.6M35.1M5.18M
Short-term investments039.9M
Current assets121.4M103.8M36.8M71.9M84.9M35.1M45.2M
Property, plant and equipment1.64M2.19M3.21M4.42M3.84M2.79M425.0K
Total assets125.2M106.9M41.2M77.7M89.2M38.3M45.9M
Accounts payable1.13M237.0K422.0K380.0K1.59M921.0K218.0K
Current liabilities9.00M37.5M14.2M5.62M5.36M4.71M1.41M
Long-term debt47.1M1.73M11.6M20.9M560.0K483.0K420.0K
Total debt011.6M20.5M22.8M560.0K483.0K420.0K
Total liabilities73.3M40.5M28.5M30.0M25.1M12.8M53.9M
Shareholders' equity51.9M66.3M12.7M47.7M64.1M-23.6M-8.04M
Shares outstanding54.9M46.8M29.1M28.9M28.7M11.6M18.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-38.3M-27.0M-34.2M-31.4M-22.2M-9.07M-5.18M
Capital spending-587.0K-16.0K-457.0K-1.30M-1.83M-1.48M-159.0K
Free cash flow-38.9M-27.0M-34.7M-32.7M-24.1M-10.5M-5.34M
Cash from investing-560.0K-16.0K-280.0K-1.30M-1.83M38.5M-35.7M
Cash from financing56.1M94.3M-121.0K20.0M71.8M490.0K22.0M
Share buybacks-121.0K71.8M
Change in cash17.2M67.2M-34.6M-12.7M47.7M29.9M-18.9M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026Current reportSEC
424B5 · ProspectusNov 12, 2026Offer documentSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 11, 2026Insider tradeSEC
144 · Notice of proposed saleSep 10, 2026Other filingsSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2026Insider tradeSEC
8-K · Current reportSep 10, 2026Management or board changeSEC
8-K · Current reportSep 9, 2026Current reportSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
8-K · Current reportJun 24, 2026Meeting outcomeSEC
8-K · Current reportJun 16, 2026Management or board changeSEC
8-K · Current reportMay 15, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 18, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
8-K · Current reportFeb 23, 2026Material contractSEC
424B5 · ProspectusFeb 20, 2026Offer documentSEC
424B5 · ProspectusFeb 19, 2026Offer documentSEC
8-K · Current reportFeb 19, 2026ResultsSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
8-K · Current reportDec 5, 2025Current reportSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
8-K · Current reportOct 14, 2025ResultsSEC
EFFECT · Notice that a registration is effectiveAug 25, 2025Other filingsSEC
8-K · Current reportAug 21, 2025Material contractSEC
CORRESP · Letter to the SECAug 20, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 20, 2025Other filingsSEC
S-3 · Registration statementAug 14, 2025Offer documentSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
144 · Notice of proposed saleJun 30, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeJun 30, 2025Big-stake noticeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
8-K · Current reportJun 24, 2025Material contractSEC
424B5 · ProspectusJun 24, 2025Offer documentSEC
8-K · Current reportJun 23, 2025Management or board changeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 6, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Management or board changeSEC
8-K · Current reportMay 28, 2025Current reportSEC
8-K · Current reportMay 22, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
8-K · Current reportApr 23, 2025Current reportSEC
8-K · Current reportMar 26, 2025Current reportSEC
4 · Change in ownershipMar 20, 2025Insider tradeSEC
4 · Change in ownershipMar 20, 2025Insider tradeSEC
4 · Change in ownershipMar 20, 2025Insider tradeSEC
4/A · Change in ownership, amendedMar 20, 2025Insider tradeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
4 · Change in ownershipMar 19, 2025Insider tradeSEC
144 · Notice of proposed saleMar 18, 2025Other filingsSEC
144 · Notice of proposed saleMar 18, 2025Other filingsSEC
144 · Notice of proposed saleMar 18, 2025Other filingsSEC
144 · Notice of proposed saleMar 17, 2025Other filingsSEC
144 · Notice of proposed saleMar 17, 2025Other filingsSEC
S-8 · Registration statement for employee plansMar 13, 2025Offer documentSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
8-K · Current reportFeb 25, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 7, 2025Big-stake noticeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
4 · Change in ownershipJan 17, 2025Insider tradeSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
144 · Notice of proposed saleJan 15, 2025Other filingsSEC
8-K · Current reportJan 13, 2025ResultsSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
144 · Notice of proposed saleJan 8, 2025Other filingsSEC
144 · Notice of proposed saleJan 8, 2025Other filingsSEC
144 · Notice of proposed saleJan 8, 2025Other filingsSEC
144 · Notice of proposed saleJan 8, 2025Other filingsSEC
144 · Notice of proposed saleJan 8, 2025Other filingsSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
SC 13G · Big-stake noticeDec 17, 2024Big-stake noticeSEC
4 · Change in ownershipDec 13, 2024Insider tradeSEC
8-K · Current reportDec 13, 2024Material contractSEC
424B5 · ProspectusDec 13, 2024Offer documentSEC
424B5 · ProspectusDec 12, 2024Offer documentSEC
8-K · Current reportDec 11, 2024Current reportSEC
4 · Change in ownershipDec 6, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
144 · Notice of proposed saleNov 29, 2024Other filingsSEC
144 · Notice of proposed saleNov 29, 2024Other filingsSEC
144 · Notice of proposed saleNov 29, 2024Other filingsSEC
144 · Notice of proposed saleNov 29, 2024Other filingsSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
4 · Change in ownershipNov 8, 2024Insider tradeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
4 · Change in ownershipOct 28, 2024Insider tradeSEC
8-K · Current reportOct 28, 2024Current reportSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
144 · Notice of proposed saleSep 23, 2024Other filingsSEC
144 · Notice of proposed saleSep 13, 2024Other filingsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
4 · Change in ownershipJul 19, 2024Insider tradeSEC
4 · Change in ownershipJul 19, 2024Insider tradeSEC
4 · Change in ownershipJul 19, 2024Insider tradeSEC

This page holds 200 of 423 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Candel Therapeutics, Inc.’s releases · as of Nov 5, 2026

Common shares
78,445,937
Fully diluted
78,445,937

Fully diluted

LineSharesAs of
Common shares78,445,937Nov 5, 2026

Share count over time

CountShares
Nov 5, 202678,445,937

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Fidelity11.6M14.7%US$121MSep 30, 2026
BlackRock5.18M6.6%US$54.1MSep 30, 2026
Vanguard4.02M5.1%US$42MSep 30, 2026
State Street3.81M4.9%US$39.7MSep 30, 2026
Portolan Capital Management, LLC3.54M4.5%US$36.9MSep 30, 2026
Acorn Capital Advisors, LLC3.5M4.5%US$36.5MSep 30, 2026
Saturn V Capital Management LP3.48M4.4%US$36.3MSep 30, 2026
Rtw Investments, LP3.21M4.1%US$33.5MSep 30, 2026
Geode Capital1.71M2.2%US$17.8MSep 30, 2026
Millennium971K1.2%US$10.1MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
UBS948K1.2%US$9.9MSep 30, 2026
Schwab623K0.79%US$6.51MSep 30, 2026
Kennedy Capital Management LLC622K0.79%US$6.49MSep 30, 2026
Northern Trust518K0.66%US$5.41MSep 30, 2026
Sands Capital Alternatives, LLC406K0.52%US$4.24MSep 30, 2026
Citadel374K0.48%US$3.9MSep 30, 2026
Point72 Asset Management, L.P.335K0.43%US$3.5MSep 30, 2026
Susquehanna327K0.42%US$3.41MSep 30, 2026
Goldman Sachs318K0.40%US$3.32MSep 30, 2026
Wellington313K0.40%US$3.27MSep 30, 2026
Bank of America293K0.37%US$3.06MSep 30, 2026
BNY208K0.27%US$2.17MSep 30, 2026
Tanager Wealth Management LLP198K0.25%US$2.07MSep 30, 2026
XTX Topco Ltd195K0.25%US$2.03MSep 30, 2026
Hrt Financial LP188K0.24%US$1.96MSep 30, 2026
Qube Research & Technologies Ltd186K0.24%US$1.94MSep 30, 2026
Morgan Stanley172K0.22%US$1.8MSep 30, 2026
Trexquant Investment LP152K0.19%US$1.58MSep 30, 2026
ACT Capital Partners, L.P.151K0.19%US$1.57MSep 30, 2026
Nuveen140K0.18%US$1.46MSep 30, 2026
D. E. Shaw & Co., Inc.132K0.17%US$1.37MSep 30, 2026
Jump Financial, LLC131K0.17%US$1.36MSep 30, 2026
Pinnacle Financial Group, Inc.117K0.15%US$1.22MSep 30, 2026
Commonwealth Equity Services, LLC116K0.15%US$1.21MSep 30, 2026
Formula Growth LTD105K0.13%US$1.1MSep 30, 2026
Alps Advisors Inc101K0.13%US$1.06MSep 30, 2026
Squarepoint Ops LLC97,7490.12%US$1.02MSep 30, 2026
Rafferty Asset Management, LLC94,6050.12%US$988KSep 30, 2026
Creative Planning91,1510.12%US$952KSep 30, 2026
Tidal Investments LLC88,0970.11%US$920KSep 30, 2026
Tema ETFS LLC88,0970.11%US$920KSep 30, 2026
Rhumbline Advisers76,0820.10%US$794KSep 30, 2026
Barclays72,0740.09%US$752KSep 30, 2026
HB Wealth Management, LLC67,8020.09%US$708KSep 30, 2026
Torrey Growth & Income Advisors65,5560.08%US$711KSep 30, 2026
AllianceBernstein60,7200.08%US$634KSep 30, 2026
Wexford Capital LP60,3690.08%US$630KSep 30, 2026
Martingale Asset Management L P59,3840.08%US$620KSep 30, 2026
Fisher Asset Management, LLC57,8000.07%US$603KSep 30, 2026
DWS55,2100.07%US$576KSep 30, 2026

This page holds 50 of 137 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Select Biotechnology Portfolio4.86M6.2%US$40.4MMay 31, 2026
Fidelity Growth Company Fund2.11M2.7%US$17.5MMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.02M2.6%US$20.8MJun 30, 2026
Vanguard Total Stock Market Index Fund1.97M2.5%US$20.3MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund1.81M2.3%US$15.1MMay 31, 2026
iShares Russell 2000 ETF1.65M2.1%US$17MJun 30, 2026
Fidelity Small Cap Index Fund693K0.88%US$6.94MJul 31, 2026
Vanguard Extended Market Index Fund659K0.84%US$6.79MJun 30, 2026
Fidelity Growth Company K6 Fund602K0.77%US$5MMay 31, 2026
iShares Russell 2000 Growth ETF556K0.71%US$5.73MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Series Growth Company Fund556K0.71%US$4.61MMay 31, 2026
iShares Biotechnology ETF411K0.52%US$4.23MJun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF265K0.34%US$2.72MJun 30, 2026
Vanguard Russell 2000 Index Fund234K0.30%US$1.94MMay 31, 2026
iShares Micro-Cap ETF211K0.27%US$2.18MJun 30, 2026
Fidelity Extended Market Index Fund200K0.25%US$1.66MMay 31, 2026
Schwab Small-Cap Index Fund154K0.20%US$1.54MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF121K0.15%US$1.25MJun 30, 2026
Master Small Cap Index Series118K0.15%US$1.22MJun 30, 2026
Nuveen Small Cap Blend Index Fund84,1410.11%US$842KJul 31, 2026
ALPS Medical Breakthroughs ETF75,5000.10%US$627KMay 31, 2026
EQ/2000 Managed Volatility Portfolio68,9560.09%US$710KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares68,7720.09%US$688KJul 31, 2026
Fidelity Total Market Index Fund66,6010.08%US$553KMay 31, 2026
Fidelity Series Total Market Index Fund57,8690.07%US$480KMay 31, 2026
Fidelity Small Cap Growth Index Fund55,4930.07%US$572KJun 30, 2026
Schwab Total Stock Market Index Fund49,3960.06%US$494KJul 31, 2026
LVIP State Street Small-Cap Index Fund45,5000.06%US$469KJun 30, 2026
Fidelity Nasdaq Composite Index Fund41,6720.05%US$346KMay 31, 2026
Nuveen Equity Index Fund39,9420.05%US$400KJul 31, 2026
Vanguard Russell 2000 Growth Index Fund38,6480.05%US$321KMay 31, 2026
AlphaCentric Life Sciences and Healthcare Fund36,6830.05%US$378KJun 30, 2026
Virtus Biotech Clinical Trials Etf36,3100.05%US$363KJul 31, 2026
Vanguard Balanced Index Fund34,3600.04%US$354KJun 30, 2026
EQ/Small Company Index Portfolio33,1600.04%US$342KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund32,7700.04%US$338KJun 30, 2026
Small Cap Index Fund32,6950.04%US$337KJun 30, 2026
iShares Russell 2000 Value ETF32,6720.04%US$337KJun 30, 2026
Fidelity ZERO Total Market Index Fund32,4860.04%US$325KJul 31, 2026
Global X Russell 2000 ETF30,2660.04%US$303KJul 31, 2026
MetLife Russell 2000 Index Portfolio21,5240.03%US$222KJun 30, 2026
Fidelity ZERO Extended Market Index Fund21,0720.03%US$211KJul 31, 2026
ATM Small Cap Managed Volatility Portfolio20,3010.03%US$209KJun 30, 2026
iShares Russell 3000 ETF20,1650.03%US$208KJun 30, 2026
Biotechnology Ultrasector Profund19,2980.02%US$193KJul 31, 2026
Small-Cap Index Portfolio18,1230.02%US$187KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio17,8000.02%US$183KJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund17,2260.02%US$172KJul 31, 2026
Small Cap Index Fund16,4090.02%US$136KMay 31, 2026
Goldman Sachs Absolute Return Tracker Fund14,4700.02%US$149KJun 30, 2026

This page holds 50 of 116 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Tak Paul Peter
Director, Officer: Chief Executive Officer
Sale59,379USD 10.46US$621KSep 11, 2026
Tak Paul Peter
Director, Officer: Chief Executive Officer
Sale220,866USD 11.50US$2.54MSep 10, 2026
Tyagarajan Seshu
Officer: Chief Technology Officer
Sale7,000USD 12.00US$84,000Aug 17, 2026
Barone Francesca
Officer: Chief Scientific Officer
Sale23,447USD 10.06US$236KJun 29, 2026
Tyagarajan Seshu
Officer: Chief Technology Officer
Sale7,000USD 10.02US$70,140Jun 29, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC9.30%3.92MDec 31, 2024Schedule 13G
Paul B Manning7.90%5.79MDec 16, 2024Schedule 13D
BlackRock, Inc.6.60%4.83MJun 30, 2026Schedule 13G
Anders Hove5.20%2.58MJun 25, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Joseph Papa
Other companies: Milestone Pharmaceuticals Inc. (Independent Non-Executive Director · Since at least Sep 3, 2024); Emergent BioSolutions Inc. (President and Chief Executive Officer · Since at least Feb 21, 2024); Bausch + Lomb Corporation (See Remarks, Director · May 5, 2022 – May 5, 2022 · Past); Prometheus Biosciences Inc (Director · Mar 11, 2021 – Jun 16, 2023 · Past); Bausch Health Companies Inc. (Director · May 2, 2016 – May 10, 2022 · Past); Perrigo Company plc (Director · Oct 9, 2006 – Feb 26, 2016 · Past)
Chairman · Since at least Aug 8, 2022
Jason Amello
Other companies: TScan Therapeutics, Inc. (Chief Financial Officer · Since at least Jan 29, 2024); Acer Therapeutics Inc (Director · Jan 2, 2020 – Mar 14, 2023 · Past); Akebia Therapeutics, Inc. (SVP, CFO & Treasurer · Apr 11, 2019 – Feb 28, 2020 · Past)
Chief Financial Officer · Sep 21, 2022 – Nov 28, 2023 · Past
Diem Nguyen
Other companies: SIGA Technologies Inc. (Chief Executive Officer, Director · Since at least Jan 27, 2024); Verrica Pharmaceuticals Inc. (Director · Since at least Jun 9, 2020)
Director · Since at least Jul 26, 2021
Gary J. Nabel
Other companies: OPKO Health, Inc. (President and CEO of ModeX Therapeutics, Chief Innovation Officer · Since at least May 12, 2026); SIGA Technologies Inc. (Board Member · Jun 10, 2026 – Nov 10, 2026 · Past)
President · Since at least Nov 5, 2026
Maha Radhakrishnan
Other companies: Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Jun 1, 2025); Alto Neuroscience, Inc. (Director · Mar 8, 2024 – Mar 8, 2024 · Past)
Director · Since at least Jun 4, 2025
Edward J Benz Jr
Other companies: Deciphera Pharmaceuticals LLC (Director · Jun 11, 2024 – Jun 11, 2024 · Past)
Director · Since at least Jun 26, 2024
John J Canepa
Other companies: Harvard Apparatus Regenerative Technology Inc (Director · Oct 16, 2013 – Mar 14, 2018 · Past)
Chief Financial Officer · Jul 26, 2021 – Feb 28, 2022 · Past
Paul B. Manning
Other companies: Verrica Pharmaceuticals Inc. (Chairman · Since at least Oct 22, 2026)
Chair of the Board · Since at least Sep 10, 2026
Shaan-Chirag C Gandhi
Other companies: Vigil Neuroscience Inc (Director · Jan 6, 2022 – Jan 6, 2022 · Past)
Director · Jul 26, 2021 – Jul 26, 2021 · Past
W. Garrett Nichols
Other companies: Chimerix Inc (Chief Medical Officer · Sep 2, 2014 – Feb 7, 2020 · Past)
Chief Medical Officer · Since at least Sep 12, 2022
All 29 people
PersonSeat
Charles SchochChief Financial Officer · Since at least Oct 14, 2025
Christopher MartellDirector · Since at least Jul 26, 2021
Edward J. BenzPresident · Since at least Nov 5, 2026
Elizabeth JaffeeDeputy Director · Since at least Mar 18, 2025
Francesca BaroneChief Scientific Officer · Since at least Feb 3, 2022
Henry BremDirector, Department of Neurosurgery · Since at least Nov 17, 2025
James P. AllisonChief of the Department of Immunology · Since at least Nov 17, 2025
Laura K AguilarChief Medical Officer · Jul 26, 2021 – Jul 29, 2021 · Past
Maria OstrovskyGeneral Counsel · Since at least Oct 22, 2026
Mark SimsChief Commercial Officer · Since at least Jul 6, 2026
Martine ZimmermannDirector · Since Sep 8, 2026
Nicoletta LoggiaDirector · Since at least Jun 7, 2023
Paul Peter TakPresident & Chief Executive Officer · Since at least Sep 10, 2026
Philip KantoffCo-Founder, Convergent Therapeutics · Since at least Nov 17, 2025
Roy HerbstDirector, Dartmouth Cancer Center · Since at least Jul 1, 2026
Seshu TyagarajanChief Technology Officer · Since at least Nov 17, 2025
Susan StewartChief Regulatory Officer · Since at least Nov 5, 2026
Theodore JenkinsVice President · Since at least Jul 9, 2026
Udi MeiravDirector · Jul 26, 2021 – Jul 26, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about Candel Therapeutics, Inc.